Pharmaceutical Advanced Manufacturing: An Industry Transformation Driven by Intelligence, Regulation, and Capital

Authors: Xu Shuxiang, Gu Weijun, Cui Zhanjun

As a quintessential industry characterized by the convergence of intellectual intensity, regulatory rigor, and capital intensity, the pharmaceutical sector is undergoing unprecedented industrial upgrading and technological revolution in its manufacturing processes. Advanced pharmaceutical manufacturing not only signifies advancements in production technologies but also drives innovation in management systems. Against the backdrop of accelerating technological development, rising public expectations for drug quality, increasingly stringent regulations, escalating R&D costs, and intensifying market competition, advanced pharmaceutical manufacturing has become a key strategic choice for pharmaceutical companies to enhance competitiveness and ensure supply chain security.

Advanced pharmaceutical manufacturing encompasses the continuous improvement of specific aspects or stages of existing drug production processes, workflows, and equipment. This includes optimizing particular segments of production lines or introducing advanced hardware and software technologies to achieve digitalization, visualization, and precise control of the manufacturing process, thereby enhancing consistency in drug quality, production efficiency, and regulatory compliance. Common technological approaches include the implementation of Manufacturing Execution Systems (MES) and Process Analytical Technology (PAT), which represent the primary means of technological upgrading for most pharmaceutical companies today.

Advanced pharmaceutical manufacturing is increasingly characterized by a higher-level integration of “continuity, intelligence, and system integration.” This represents a profound transformation in manufacturing models that transcends the application of isolated technologies, emphasizing systemic convergence and data-driven operations. By building highly integrated and adaptive intelligent production systems capable of real-time sensing, analysis, prediction, and optimization of the entire production process, the industry is achieving a leap from “post-production testing” to “real-time proactive control.” This shift enables more advanced Quality by Design (QbD) and flexible manufacturing. Examples include the role of Blow-Fill-Seal (BFS) technology in ensuring sterility; continuous manufacturing, which meets the requirement for seamless, end-to-end production from raw materials to finished products, thereby breaking away from the traditional “batch manufacturing” concept; and new manufacturing technologies such as platform-based mRNA vaccine production, personalized custom manufacturing of cell and gene therapy products, and 3D printing. These innovations cross-disciplinary boundaries by integrating the latest advancements in biotechnology, information technology, materials science, and precision engineering. They not only reshape the definition of “pharmaceuticals” themselves but also reconfigure the form of the “factory,” thereby meeting the emerging industrial demands for personalization and decentralization.

Incremental Improvements and Revolutionary Transformations in Advanced Pharmaceutical Manufacturing: Contextual Applications and Strategic SelectionIncremental improvements and revolutionary transformations in advanced pharmaceutical manufacturing each have their applicable scenarios. Rational selection should be based on corporate objectives, product characteristics, market conditions, resource availability, and other factors. Incremental improvements are more suitable for enhancing efficiency and quality control within the lifecycle of existing products. For instance, optimizing formulation production lines through technologies such as automation equipment and Process Analytical Technology (PAT) can significantly reduce energy consumption and improve batch consistency in the short term. With controllable investment and lower risk, this approach is the preferred path for most enterprises seeking steady upgrades in products and markets.In contrast, revolutionary transformations are applicable to new challenges or opportunities in market competition, or to the production of innovative therapeutic drugs/modalities. Such transformations often involve substantial investment and high uncertainty, but they serve as critical shortcuts for seizing future competitive advantages and resolving key bottlenecks. The two approaches are not mutually exclusive; rather, they constitute different dimensions of the industry’s overall evolution: pragmatic improvements support the core business foundation, accumulating capital and experience for innovation, while revolutionary breakthroughs open up new growth spaces and drive the upgrading of the entire industrial ecosystem.

In its 2014 Emerging Technology Program (ETTP), the U.S. Food and Drug Administration (FDA) stated that “advanced pharmaceutical manufacturing technologies” is a collective term for emerging production technologies in the pharmaceutical industry, primarily referring to innovative methods or technologies that can significantly improve drug manufacturing processes. Publicly available information indicates that the FDA has emphasized different advanced pharmaceutical manufacturing technologies at various stages. Previously, blow-fill-seal technology was regarded as a representative advanced technique for sterile production. More recently, breakthroughs have been driven mainly by continuous manufacturing and 3D printing. Currently, major countries and regions in the global pharmaceutical industry are actively exploring the application of artificial intelligence in pharmaceutical manufacturing.

Regardless of how advanced pharmaceutical manufacturing technologies are evaluated, the primary objectives of advocating for and adopting such technologies are to ensure and improve drug quality, enhance production efficiency, address drug shortages, accelerate time-to-market, reduce costs while increasing efficiency, and promote energy conservation and environmental protection. Advanced manufacturing manifests differently across various stages of development, and specific advanced manufacturing technologies exhibit distinct developmental forms and life cycles depending on their application scenarios.

Advanced pharmaceutical manufacturing is fundamentally characterized by its intellectual intensity, which is manifested across three key dimensions: first, high-level innovation during the R&D phase, necessitating collaborative breakthroughs by interdisciplinary teams; second, complex technological integration in the production phase, requiring engineering and technical personnel to possess cutting-edge knowledge and information across multiple domains; and third, continuous optimization during the maintenance phase, relying on the in-depth application of process management, data science, and related disciplines.

In knowledge-intensive industries, knowledge accumulation and organizational learning capabilities have become key determinants of manufacturing innovation. Advanced pharmaceutical manufacturing requires not only investment in technical hardware but also support from complementary software systems and management service frameworks. Enterprises must establish effective knowledge management systems to organize intellectually intensive work content, information, and processes, thereby making tacit knowledge explicit, individual knowledge organized, and transient knowledge systematic.

Pharmaceutical companies adopting advanced manufacturing can accelerate their learning curve through multiple approaches: establishing internal expert networks to facilitate the integration and sharing of top-tier intellectual capital and best practices; fostering industry-academia-research-application collaborations to build a multidimensional, comprehensive knowledge and intellectual resource pool that spans disciplines, fields, and departments; and implementing a phased innovation strategy that continuously optimizes the allocation and combination of intellectual resources in production applications. This strategy begins with relatively mature advanced manufacturing technologies and gradually expands toward more complex, novel advanced manufacturing technologies and their management systems, progressing from pilot-scale trials to commercial production, and from large-scale commercial manufacturing to personalized, customized, and flexible production.

Professor Liu Qiang of Beihang University is a renowned expert in the field of intelligent manufacturing. At the “2024 China Pharmaceutical Engineering Technology Conference and the 14th Annual Meeting of the Chinese Association of Pharmaceutical Equipment Engineering,” he once again emphasized the “Three Don’ts Principle” of intelligent manufacturing: “Do not pursue automation on the basis of outdated processes; do not pursue informatization on the basis of outdated management practices; and do not pursue intelligence without a foundation of digitalization and networking.” This “Three Don’ts Principle” represents an intellectually optimized assessment and summary drawn from lessons learned and developmental achievements through countless theoretical and practical explorations in the field of intelligent manufacturing, offering valuable guidance for the pragmatic advancement of advanced pharmaceutical manufacturing.

The manifestation of intellectual intensity also lies in how to efficiently mobilize resources from all parties to promote the positive development and progress of the pharmaceutical industry. This includes formulating and revising policies, regulations, and technical standards to strengthen the construction of technology and supply chains while ensuring the safety of production processes and product quality, thereby advancing advanced pharmaceutical manufacturing. It also encompasses technological progress and management development, with a particular emphasis on highlighting the cost-effectiveness ratio of advanced pharmaceutical manufacturing amidst the evolution of the pharmaceutical market and industry.

The pharmaceutical industry is highly regulated. Advanced pharmaceutical manufacturing, a critical component of this industry, requires striking a balance between compliance and innovation. It reflects the regulatory policies, regulations, and technical standards applicable at specific stages, while simultaneously driving continuous improvement and refinement of these policies and standards by innovating to overcome outdated regulatory requirements.

Regulatory oversight encompasses every stage of the pharmaceutical lifecycle—from R&D, registration, manufacturing, and distribution to clinical application—and also reflects regulatory requirements related to industry, environmental protection, and market access at both national and regional levels. Advanced pharmaceutical manufacturing demonstrates industry leadership and competitive market advantages domestically, while internationally it exhibits regulatory compliance and certification alignment in regulated markets, as well as growing regulatory influence in emerging markets. A close interactive relationship exists between advanced pharmaceutical manufacturing and regulation: they mutually constrain and promote each other, with the shared goals of ensuring drug safety, efficacy, quality controllability, and supply security, while simultaneously driving industrial innovation and efficiency improvements.

Regulation can be viewed as the “boundary” and “framework” of advanced pharmaceutical manufacturing, while also serving as “standards” and “guidance.” Pharmaceutical regulatory agencies—such as China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), the European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)—have each established relatively comprehensive drug regulatory systems tailored to their respective jurisdictions, regulatory targets, and service models, underpinned by their own legal frameworks. These systems cover the entire lifecycle of pharmaceutical products and offer mutual reference value. With the global advancement of the pharmaceutical and healthcare industries, the increasing prevalence of common health challenges faced by humanity, and the rapid development of global trade and service exchanges, the international expansion of pharmaceutical imports and exports, contract manufacturing, and production supply chains has flourished. Consequently, the global convergence of pharmaceutical regulatory regulations and technical standards is gradually becoming evident. In May 2017, the NMPA officially became a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The implementation of the vast majority of ICH guidelines in China signifies that the country has achieved internationally recognized standards in areas such as drug registration applications, review and approval processes, and quality control. In November 2023, the NMPA formally applied to join the Pharmaceutical Inspection Co-operation Scheme (PIC/S), marking a critical step in aligning China’s Good Manufacturing Practice (GMP) standards with international norms. Meanwhile, industrial policies, market management practices, and medical service regulations vary across different countries and regions. Compliance requires adherence not only to domestic pharmaceutical regulatory policies, regulations, and technical standards but also to the regulatory requirements of counterpart jurisdictions in international business operations. The “standards, boundaries, and framework” of advanced pharmaceutical manufacturing are all shaped within the context of these diverse regulatory requirements.

Meanwhile, the industry must also carefully appreciate the “guiding” role of regulation in advanced pharmaceutical manufacturing. In 2014, the FDA launched the “Emerging Technology Program,” encouraging the use of technology to improve drug manufacturing processes. In January 2025, it issued the “Advanced Manufacturing Technology Designation Program for Drugs,” which clarifies that Advanced Manufacturing Technologies (AMT) for drugs should be innovative. By integrating new technical approaches, employing existing technologies in innovative ways, or applying production methods in new areas lacking clear best practices or prior experience, AMT can enhance the quality, reliability, and robustness of drug supply, address drug shortages, and accelerate time-to-market for medicines.

In December 2024, the “Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Drug and Medical Device Supervision to Promote High-Quality Development of the Pharmaceutical Industry” clearly stated that by 2027, laws, regulations, and systems for drug and medical device supervision would be further improved; the regulatory system, mechanisms, and methods would better align with the needs of pharmaceutical innovation and high-quality industrial development; the quality and efficiency of review and approval for innovative drugs and medical devices would be significantly enhanced; lifecycle supervision would be substantially strengthened; quality and safety levels would be comprehensively improved; and a regulatory system compatible with pharmaceutical innovation and industrial development would be established. By 2035, the quality, safety, efficacy, and accessibility of drugs and medical devices will be fully guaranteed; the pharmaceutical industry will possess stronger innovation capabilities and global competitiveness; and regulatory modernization will be basically achieved.In April 2025, the “Implementation Plan for Digital and Intelligent Transformation of the Pharmaceutical Industry (2025–2030),” issued by China’s Ministry of Industry and Information Technology along with six other departments, specified that by 2027, significant progress would be made in the digital and intelligent transformation of the pharmaceutical industry, with markedly enhanced competitiveness across the entire pharmaceutical industry chain and improved lifecycle quality management driven by digital and intelligent technologies. By 2030, large-scale pharmaceutical industrial enterprises will have basically achieved full coverage of digital and intelligent transformation; integration and innovation capabilities of digital and intelligent technologies will be substantially boosted; the data system across the entire pharmaceutical industry chain will be further refined; and the ecosystem for digital and intelligent transformation of the pharmaceutical industry will be further strengthened.

In January 2021, the National Medical Products Administration (NMPA) implemented the Administrative Measures for Post-Marketing Changes of Drugs (Trial). In 2024, it issued the Pilot Work Plan for Optimizing the Review and Approval of Clinical Trials of Innovative Drugs. In June 2025, the Center for Drug Evaluation (CDE) of the NMPA publicly solicited comments on the Scope, Classification, and Definitions of Advanced Therapy Medicinal Products (Draft for Comments)...

It is evident that both domestic and international authorities are issuing policy documents, regulations, and related work plans to clearly encourage the development of advanced pharmaceutical manufacturing technologies and key focus areas, clarify regulatory requirements, and provide the industry with actionable pathways for application and implementation. These policies not only create room for technological innovation and industrial upgrading but also incorporate cutting-edge practices into the regulatory framework through institutionalized mechanisms, reflecting a modern governance philosophy that combines “baseline constraints” with “directional guidance.”

The rapid advancement of advanced pharmaceutical manufacturing technologies is also driving profound scientific and paradigmatic innovations in global drug regulatory systems, necessitating the development of new evaluation tools, modeling approaches, and compliance standards within regulatory science to validate evolving process controls, production operations, and quality assurance systems.

Characterized by being both intelligence-intensive and regulation-intensive, the pharmaceutical industry also exhibits significant capital-intensive features. The research and development of a single innovative drug often requires an investment ranging from hundreds of millions to billions of yuan; constructing a production facility compliant with Good Manufacturing Practice (GMP) standards typically entails an investment of tens to hundreds of millions of yuan; and daily operational and maintenance costs also represent substantial expenditures. The industry’s stringent requirements for technical personnel and management professionals result in high human resource costs. With the rapid advancement of complex formulations and biopharmaceuticals, the cost of certain raw materials can easily reach millions or even tens of millions of yuan, necessitating the minimization of errors in the manufacturing process to significantly reduce waste. Against this backdrop of high capital investment, advanced manufacturing technologies are receiving increasing attention, and any innovation in manufacturing technology must undergo rigorous economic evaluation.

The market advantages of advanced pharmaceutical manufacturing are reflected in the following aspects: First, it reasonably reduces early capital investment. For instance, continuous manufacturing equipment typically occupies only 1/10 to 1/5 of the footprint of batch processing equipment, which not only reduces the required facility construction area and personnel operations but may also lower equipment investment costs. Second, it improves equipment utilization. The automation, continuity, digitalization, and systematic development inherent in advanced manufacturing can significantly reduce cleaning and preparation time between batches and across upstream and downstream processes, thereby enhancing production efficiency and lowering production costs. Third, it reduces quality-related costs. Advanced manufacturing optimizes production processes through measures such as real-time in-line monitoring, which can substantially decrease scrap rates and rework costs. Fourth, it accelerates time-to-market. Advanced manufacturing facilitates product finalization, reduces regulatory approval timelines, and shortens manufacturing cycles, enabling products to reach the market earlier and generate revenue sooner.

It is also important to recognize that the challenges associated with advanced pharmaceutical manufacturing are ever-present and continuously evolving. Pharmaceutical companies that are among the first to adopt advanced manufacturing must contend with substantial investments and adaptive training related to new technologies, equipment, and systems. These high costs encompass not only the procurement and installation of expensive novel equipment but also the time and resource expenditures for associated process validation, stringent facility modifications, change management, and the development of technical teams. Furthermore, as frontier technologies, advanced manufacturing processes and control systems initially face challenges related to technological instability and incompatibility. This necessitates sustained, significant resource allocation for commissioning, optimization, and iteration. Achieving this requires extensive, multi-level collaboration among pharmaceutical companies, technology providers, equipment manufacturers, and regulatory authorities, all of which impose specific demands on capital costs.

Currently, the pharmaceutical industry faces pressures such as price reductions, volume contraction, and overcapacity driven by centralized procurement of generic drugs. At the same time, it must work to restore the value of medicines, enhance quality safety and supply chain standards, and meet unmet domestic clinical and health needs. Moreover, it must seize market opportunities for global cooperation and competition amid the international convergence of regulatory frameworks and technical standards. Focusing on and adopting advanced pharmaceutical manufacturing has become an inevitable choice for pharmaceutical companies to gain market influence and achieve greater profits in this new phase.

Best practices from leading companies indicate that successful investment in advanced pharmaceutical manufacturing should adhere to the following principles: first, adopt a gradual approach by starting with pilot projects and progressively expanding their scope; second, foster ecosystem collaboration by establishing strategic partnerships with equipment suppliers, technology partners, and regulatory authorities; third, implement flexible configurations through modular design to avoid technology lock-in; and fourth, maintain a value-oriented focus on product areas that best demonstrate the advantages of advanced manufacturing.

Advanced Pharmaceutical ManufacturingAdvanced pharmaceutical manufacturing is a relative concept that consistently serves a guiding role in the development of the industry at each stage. The successful implementation of advanced pharmaceutical manufacturing relies on the synergistic interaction of three key elements: regulation, intellectual capital, and financial capital. The regulatory framework provides standards and guidance for technological innovation; intellectual resources offer technical assurance for capital investment; and capital investment supplies the material foundation necessary to meet regulatory requirements and attract intellectual resources.

In advancing pharmaceutical advanced manufacturing and promoting industrial transformation and upgrading, China’s pharmaceutical industry needs to explore implementation pathways suited to national conditions, as well as develop distinct strategies and practical measures for international regulatory markets and emerging markets. The development of China’s pharmaceutical industry exhibits multimodal, multi-level, and multidirectional characteristics. Whether traditional pharmaceutical companies, contract development and manufacturing organizations (CDMOs), or novel biopharmaceutical and cell therapy firms, many have made successful explorations in the field of current pharmaceutical advanced manufacturing and are actively pursuing future advanced manufacturing technologies. In November 2022, the Chinese Pharmaceutical Association for Equipment Engineering (CPAPE) convened the “Advanced Manufacturing Conference for Biopharmaceuticals” in Wuxi, formally launching a comprehensive advocacy for pharmaceutical advanced manufacturing. Designating this as an annual priority, CPAPE continues to mobilize its member units, council members, pharmaceutical industry enterprises, experts, and scholars to participate in advancing pharmaceutical advanced manufacturing through academic and industrial exchange events, research projects, and industry surveys.

Regarding the approaches and measures for enterprises to implement advanced pharmaceutical manufacturing, we have summarized five key points for reference: 1. Formulate a clear manufacturing strategy by integrating advanced manufacturing into the overall corporate development strategy, with defined technology roadmaps and investment plans; 2. Build a multi-tiered talent system by establishing multidisciplinary technical teams through recruitment, training, and collaboration; 3. Engage in standardization and ecosystem development by actively communicating with regulatory authorities, participating in the formulation of relevant technical standards and guidelines, and fostering an industrial innovation ecosystem; 4. Adopt appropriate innovation models by selecting independent development, collaborative R&D, or technology licensing based on the enterprise’s scale and characteristics; 5. Prioritize the accumulation of data assets by establishing robust data collection and management systems to lay the foundation for continuous optimization and intelligent applications.

Advanced pharmaceutical manufacturing always represents the future direction of the pharmaceutical industry. We sincerely hope that China’s pharmaceutical industry, while carrying out routine operations, will prioritize and actively engage in advanced pharmaceutical manufacturing, promote the deep integration of technological and industrial innovation, continuously enhance industrial competitiveness and collaborative influence, focus on improving total factor productivity, and inject strong momentum into developing new-quality productive forces and achieving high-quality development.

References (omitted)

(The authors of this article, Xu Shuxiang, Gu Weijun, and Cui Zhanjun, serve respectively as the Secretary-General, Chairman of the Expert Committee, and Chairman of the Board of Supervisors of the China Pharmaceutical Equipment Engineering Association. Adhering to the sixteen-character work guideline of “government-enterprise communication, standard development, international cooperation, and industry services,” the China Pharmaceutical Equipment Engineering Association is committed to advancing advanced pharmaceutical manufacturing and promoting the high-quality development of China’s pharmaceutical industry.)